3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Neoplasms
2
Meningioma
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Surveys and Questionnaires
7
Standard of Care
5
Sirolimus
5
Bevacizumab
5
temsirolimus
4
Interviews as Topic
4
Paclitaxel
3
olaparib
2
Vorinostat
2
Olanzapine
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Everolimus
2
Erlotinib Hydrochloride
2
Dasatinib
2
Cetuximab
2
zaleplon
1
vistusertib
1
tilsotolimod
1
pazopanib
1
olanzapine-fluoxetine combination
1
nimotuzumab
1
liposomal doxorubicin
1
capivasertib
1
apatinib
1
Videotape Recording
1
Vemurafenib
1
Valproic Acid
1
Trastuzumab
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Cancer
×
vistusertib
×
Clear all
NCT02193633
2024-09-26
TAX-TORC
Royal Marsden NHS Foundation Trust
Phase 1
Completed
90 enrolled